Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase I Study of Isotretinoin in Patients With Recessive Dystrophic Epidermolysis Bullosa

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2001 by FDA Office of Orphan Products Development.
Recruitment status was  Active, not recruiting
University of North Carolina
Information provided by:
FDA Office of Orphan Products Development Identifier:
First received: April 10, 2001
Last updated: June 23, 2005
Last verified: May 2001


I. Determine the safety of isotretinoin in patients with recessive dystrophic epidermolysis bullosa.

Condition Intervention Phase
Epidermolysis Bullosa
Drug: isotretinoin
Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by FDA Office of Orphan Products Development:

Estimated Enrollment: 20
Study Start Date: October 2000
Detailed Description:


Patients receive oral isotretinoin daily for 8 months in the absence of disease progression or unacceptable toxicity.


Ages Eligible for Study:   15 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


--Disease Characteristics--

  • Diagnosis of recessive dystrophic epidermolysis bullosa (RDEB) RDEB Hallopeau-Siemens OR RDEB non-Hallopeau-Siemens
  • Concurrent enrollment in the National Epidermolysis Bullosa Registry
  • No regional or distant metastasis in patients with previous or concurrent squamous cell carcinoma

--Patient Characteristics--

  • Hepatic: No clinically significant hypertriglyceridemia No clinically significant hepatic dysfunction
  • Renal: No clinically significant renal dysfunction
  • Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00014729

Sponsors and Collaborators
University of North Carolina
Study Chair: Jo-David Fine University of North Carolina
  More Information

No publications provided Identifier: NCT00014729     History of Changes
Other Study ID Numbers: 199/15738, UNCCH-FDR001796
Study First Received: April 10, 2001
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Keywords provided by FDA Office of Orphan Products Development:
dermatologic disorders
epidermolysis bullosa
genetic diseases and dysmorphic syndromes
rare disease

Additional relevant MeSH terms:
Epidermolysis Bullosa
Congenital Abnormalities
Genetic Diseases, Inborn
Skin Abnormalities
Skin Diseases
Skin Diseases, Genetic
Skin Diseases, Vesiculobullous
Dermatologic Agents
Pharmacologic Actions
Therapeutic Uses processed this record on February 27, 2015